Watch MLYS. Know when insiders buy.
One email the day a filing lands. Free.
Work order
41
WATCH · insiders 41, shorts 41
Insiders, 90 days
−$193K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.5BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$349.6MNET CASH $138.2M52W 22.50 – 47.33SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$246M | −$241.1M | — | -2.85 | −$32.6M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$45.3M | −$39.3M | — | -0.47 | −$39.5M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$38.3M | −$32.2M | — | -0.35 | −$37.9M | $15K | −$37.9M | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$41.1M | −$36.9M | — | -0.52 | −$28.9M | $0 | −$28.9M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$46.7M | −$43.3M | — | -0.66 | −$30.2M | $0 | −$30.2M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$44.4M | −$42.2M | — | -0.79 | −$45.5M | $0 | −$45.5M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$51.8M | −$48.9M | — | -0.98 | −$66.8M | $0 | −$66.8M | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$60.1M | −$56.3M | — | -1.13 | −$50.2M | $37K | −$50.2M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$45.2M | −$41M | — | -0.83 | −$30.1M | $0 | −$30.1M | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$35.4M | −$31.5M | — | -0.70 | −$19.1M | $59K | −$19.2M | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$27.7M | −$24.4M | — | -0.63 | −$29M | $0 | −$29M | Feb 12 |
| Q3 2023 · Sep 30 | — | — | — | −$26.3M | −$22.8M | — | -0.57 | −$19M | $0 | −$19M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$170.6M | −$154.7M | — | -2.29 | −$142.4M | $15K | −$142.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$192.4M | −$177.8M | — | -3.66 | −$166.3M | $96K | −$166.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$84.7M | −$71.9M | — | -1.99 | −$81.2M | $0 | −$81.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$31.5M | −$29.8M | — | -5.77 | −$29.2M | — | — | — | — |
Every number comes from Mineralys Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.